{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T06:39:44Z","timestamp":1792823984449,"version":"4.5.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100018904","name":"Beijing Xisike Clinical Oncology Research Foundation","doi-asserted-by":"publisher","award":["Y-2024AZ (EGFR)MS-0033"],"award-info":[{"award-number":["Y-2024AZ (EGFR)MS-0033"]}],"id":[{"id":"10.13039\/100018904","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82522074"],"award-info":[{"award-number":["82522074"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32570901"],"award-info":[{"award-number":["32570901"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82322050"],"award-info":[{"award-number":["82322050"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82630085"],"award-info":[{"award-number":["82630085"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.canlet.2026.218885","type":"journal-article","created":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:01:37Z","timestamp":1791475297000},"page":"218885","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["PRODH promotes osimertinib drug-tolerant persistence in EGFR-mutant NSCLC by activating mitochondrial transcription"],"prefix":"10.1016","volume":"661","author":[{"given":"Xiang","family":"Meng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bai-Xin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dian-An","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengqi","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kecheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuanhuan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zongxi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Tao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuying","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2026.218885_bib1","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","article-title":"Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR","volume":"362","author":"Maemondo","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2026.218885_bib2","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0140-6736(16)30958-8","article-title":"Lung cancer: current therapies and new targeted treatments","volume":"389","author":"Hirsch","year":"2017","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.canlet.2026.218885_bib3","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/nrc.2017.84","article-title":"Understanding and targeting resistance mechanisms in NSCLC","volume":"17","author":"Rotow","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2026.218885_bib4","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41573-019-0044-1","article-title":"The great escape: tumour cell plasticity in resistance to targeted therapy","volume":"19","author":"Boumahdi","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.canlet.2026.218885_bib5","doi-asserted-by":"crossref","DOI":"10.1172\/JCI160152","article-title":"Targeting acetylcholine signaling modulates persistent drug tolerance in EGFR-mutant lung cancer and impedes tumor relapse","volume":"132","author":"Nie","year":"2022","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.canlet.2026.218885_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.218069","article-title":"Targeting inosine metabolism to enhance EGFR-targeted therapy in lung adenocarcinoma","volume":"634","author":"Huang","year":"2025","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2026.218885_bib7","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/s41586-021-03796-6","article-title":"Cycling cancer persister cells arise from lineages with distinct programs","volume":"596","author":"Oren","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2026.218885_bib8","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1158\/0008-5472.CAN-22-2370","article-title":"PINK1-Mediated mitophagy promotes oxidative phosphorylation and redox homeostasis to induce drug-tolerant persister cancer cells","volume":"83","author":"Li","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2026.218885_bib9","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1158\/0008-5472.CAN-24-1204","article-title":"Oxidative phosphorylation is a metabolic vulnerability of endocrine therapy-tolerant persister cells in ER+ breast cancer","volume":"85","author":"Tau","year":"2025","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2026.218885_bib10","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1038\/s41589-024-01776-1","article-title":"Mitochondria-localized MBD2c facilitates mtDNA transcription and drug resistance","volume":"21","author":"Hao","year":"2025","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.canlet.2026.218885_bib11","article-title":"Mitochondrion-localized SND1 promotes mitophagy and liver cancer progression through PGAM5","volume":"12","author":"Liang","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.canlet.2026.218885_bib12","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41422-023-00788-1","article-title":"Mitochondria-localized cGAS suppresses ferroptosis to promote cancer progression","volume":"33","author":"Qiu","year":"2023","journal-title":"Cell Res."},{"key":"10.1016\/j.canlet.2026.218885_bib13","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1086\/428142","article-title":"Functional consequences of PRODH missense mutations","volume":"76","author":"Bender","year":"2005","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.canlet.2026.218885_bib14","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41580-023-00661-4","article-title":"Mechanisms and regulation of human mitochondrial transcription","volume":"25","author":"Tan","year":"2024","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.canlet.2026.218885_bib15","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.bbrc.2020.05.141","article-title":"Phosphorylation of mitochondrial transcription factor B2 controls mitochondrial DNA binding and transcription","volume":"528","author":"Bostwick","year":"2020","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.canlet.2026.218885_bib16","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/j.cell.2017.10.036","article-title":"Structural basis of mitochondrial transcription initiation","volume":"171","author":"Hillen","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2026.218885_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2018.101076","article-title":"Metabolic reprogramming of oncogene-addicted cancer cells to OXPHOS as a mechanism of drug resistance","volume":"25","author":"Hirpara","year":"2019","journal-title":"Redox Biol."},{"key":"10.1016\/j.canlet.2026.218885_bib18","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1158\/0008-5472.CAN-22-3059","article-title":"Metabolic reprogramming driven by IGF2BP3 promotes acquired resistance to EGFR inhibitors in non-small cell lung cancer","volume":"83","author":"Lin","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2026.218885_bib19","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1038\/nchembio.2143","article-title":"Metabolic plasticity underpins innate and acquired resistance to LDHA inhibition","volume":"12","author":"Boudreau","year":"2016","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.canlet.2026.218885_bib20","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau1167","article-title":"Metabolic reprogramming toward oxidative phosphorylation identifies a therapeutic target for mantle cell lymphoma","volume":"11","author":"Zhang","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.canlet.2026.218885_bib21","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1182\/blood.2023020142","article-title":"EGR1-mediated metabolic reprogramming to oxidative phosphorylation contributes to ibrutinib resistance in B-cell lymphoma","volume":"142","author":"Liu","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2026.218885_bib22","article-title":"Enhanced oxidative phosphorylation driven by TACO1 mitochondrial translocation promotes stemness and cisplatin resistance in bladder cancer","volume":"12","author":"Deng","year":"2025","journal-title":"Adv. Sci (Weinheim, Baden-Wurttemberg, Germany)"},{"key":"10.1016\/j.canlet.2026.218885_bib23","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1128\/MCB.25.4.1354-1366.2005","article-title":"Control of mitochondrial transcription specificity factors (TFB1M and TFB2M) by nuclear respiratory factors (NRF-1 and NRF-2) and PGC-1 family coactivators","volume":"25","author":"Gleyzer","year":"2005","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.canlet.2026.218885_bib24","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/s41420-023-01691-9","article-title":"ZNF281 inhibits mitochondrial biogenesis to facilitate metastasis of hepatocellular carcinoma","volume":"9","author":"Zhao","year":"2023","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.canlet.2026.218885_bib25","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.34133\/research.1045","article-title":"Histone lactylation couples FSH-Driven lactate metabolism to mitochondrial biogenesis by enhancing HDAC4-Mediated deacetylation of PGC-1alpha in granulosa cells","volume":"9","author":"Wu","year":"2026","journal-title":"Research"},{"key":"10.1016\/j.canlet.2026.218885_bib26","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.tem.2015.06.001","article-title":"SIRT3 regulates progression and development of diseases of aging","volume":"26","author":"McDonnell","year":"2015","journal-title":"Trends Endocrinol. Metabol.: TEM (Trends Endocrinol. Metab.)"},{"key":"10.1016\/j.canlet.2026.218885_bib27","first-page":"789","article-title":"A novel Drp1 inhibitor diminishes aberrant mitochondrial fission and neurotoxicity","volume":"126","author":"Qi","year":"2013","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.canlet.2026.218885_bib28","doi-asserted-by":"crossref","first-page":"e8166","DOI":"10.15252\/emmm.201708166","article-title":"Inhibition of Drp1\/Fis1 interaction slows progression of amyotrophic lateral sclerosis","volume":"10","author":"Joshi","year":"2018","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.canlet.2026.218885_bib29","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.cell.2023.11.022","article-title":"Metabolic regulation of homologous recombination repair by MRE11 lactylation","volume":"187","author":"Chen","year":"2024","journal-title":"Cell"}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030438352600649X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030438352600649X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T06:24:47Z","timestamp":1792823087000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030438352600649X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":29,"alternative-id":["S030438352600649X"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218885","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PRODH promotes osimertinib drug-tolerant persistence in EGFR-mutant NSCLC by activating mitochondrial transcription","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218885","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"218885"}}